US Melanoma Market Share, Growth, Trends Report 2023

Gvr

Informations

• Publié par: marketresearchri123
• Publié le: 03 mai 2017
• Nombre de lectures: 1
• Langue: English

Extrait

US Melanoma Market Forecast and Analysis
Report 2023
“The US represents the largest market for
melanoma of all the countries covered in this
report. The analysts estimate that sales of branded
therapies were $836m in 2013. ”

Summary
Melanoma is the deadliest and most aggressive form of skin cancer. The major treatments for
melanoma are categorized into immunotherapies and BRAF mutation-targeted therapies. Radiant
Insights estimates the 2013 sales for melanoma at approximately $1.34 billion across the 8MM
covered in this report. The market will increase by four-fold over the forecast period, reaching
$5.64 billion in 2023 at a CAGR of 15.5%. This growth will be driven by an increase in melanoma
incident cases as well as the approval and uptake of premium-priced products, such as
PD-1targeting mAbs and BRAF/MEK inhibitor combinations. Radiant Insights expects, by the end of the
forecast period, the checkpoint immunotherapy drug class to dominate the melanoma market
(including both BRAF wild-type and mutation-positive patient segments) with an overall 67% share
of the melanoma market.
Read Complete Report with TOC @

http://www.radiantinsights.com/research/melanoma-us-drug-forecast-and-marketanalysis-to-2023
The US represents the largest market for melanoma of all the countries covered in this report. The
analysts estimate that sales of branded therapies were $836m in 2013. The US is the largest
melanoma market due to a high incidence of the disease and higher drug prices than in the 5EU,

Follow Us:

Japan, and Australia. Increased sales of melanoma therapies over the forecast period will be driven
by increasing disease incident cases across age groups, label extension of Keytruda and Opdivo as
first-line treatments for advanced melanoma patients, the approval and increasing uptake of
expensive combinations in both the immunotherapy and BRAF/MEK inhibitor categories, and the
label expansion of metastatic treatments in the lucrative adjuvant setting.
*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the
purchase.
Request a Sample Copy of This Report @

http://www.radiantinsights.com/research/melanoma-us-drug-forecast-and-marketanalysis-to-2023/request-sample
Scope
- Overview of Melanoma including epidemiology, etiology, symptoms, diagnosis, pathology and
treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the US including product Melanomacription, safety and
efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the US from 2013-2023.
- Analysis of the impact of key events as well the drivers and restraints affecting the US Melanoma
market.
Reasons To Buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for
Melanoma.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising
sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2013-2023 in the US.
See More Reports of This Category by Radiant Insights @
http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare

Follow Us:

About Radiant Insights, Inc:
Radiant Insights is a platform for companies looking to meet their market
research and business intelligence requirements. We assist and facilitate
organizations and individuals procure market research reports, helping them in
the decision making process. We have a comprehensive collection of reports,
covering over 40 key industries and a host of micro markets. In addition to over
extensive database of reports, our experienced research coordinators also offer a
host of ancillary services such as, research partnerships/ tie-ups and customized
research solutions.
Contact Details:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
28 2nd Street, Suite 3036, San Francisco, CA 94105, United States
Phone: [phone]
Toll Free: 1-888-202-9519
Email: [e-mail]
Web: http://www.radiantinsights.com/
Visit Our Blog: http://radiantinsightinc.blogspot.in/



Follow Us: